Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $5.9 million.

  • Gyre Therapeutics' Income towards Parent Company rose 10784.31% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 11279.92%. This contributed to the annual value of $16.9 million for FY2024, which is 11957.5% up from last year.
  • As of Q3 2025, Gyre Therapeutics' Income towards Parent Company stood at $5.9 million, which was up 10784.31% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' Income towards Parent Company peaked at $51.6 million during Q2 2022, and registered a low of -$101.8 million during Q4 2023.
  • In the last 5 years, Gyre Therapeutics' Income towards Parent Company had a median value of $1.6 million in 2025 and averaged -$7.5 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 45319.52% in 2021, then surged by 35909.27% in 2022.
  • Over the past 5 years, Gyre Therapeutics' Income towards Parent Company (Quarter) stood at -$20.3 million in 2021, then plummeted by 41.75% to -$28.8 million in 2022, then plummeted by 253.66% to -$101.8 million in 2023, then surged by 99.57% to -$433000.0 in 2024, then surged by 1470.9% to $5.9 million in 2025.
  • Its Income towards Parent Company was $5.9 million in Q3 2025, compared to $1.6 million in Q2 2025 and $3.7 million in Q1 2025.